Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at Canaccord Genuity Growth Conference (Live)
08/13/14 at 8:30 a.m. ET
Webcast ImageWebcast
Q2 2014 AtriCure, Inc. Earnings Conference Call (Replay)
07/24/14 at 4:30 p.m. ET

Corporate Profile

AtriCure was formed by a team with extensive experience in the medical device industry. The company is focused on developing innovative products using proprietary technology that provides doctors alternative, expedient methods to ablate tissue during surgical procedures.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$16.47 - 0.774.47%181,895
Previous CloseToday's OpenIntraday HighIntraday Low
$17.24$17.06$17.21$16.39
Exchange: NASDAQ (US Dollar)
07/31/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
07/31/14
Download Documentation Investor Presentation
04/11/14
Download Documentation 2013 Annual Report

All Recent News

DateTitle 
07/29/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following th... 
Printer Friendly Version
07/24/14AtriCure Reports Second Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $26.5 million – up 29.8% U.S. sales of $19.9 million – up 28.8% International sales of $6.6 million – up 32.9%; 29.1% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 24, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced financial results for the second quarter of 2014. “We are pleased with our performan... 
Printer Friendly Version
07/16/14AtriClip® System Surpasses 34,000 Units Sold
AtriClip is the most widely used device indicated for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 16, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), today announced that it has sold more than 34,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, quickly becoming the top selling device used for eliminating the left... 
Printer Friendly Version
07/03/14AtriCure to Announce Second Quarter 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the second quarter of 2014 on Thursday, July 24, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, July 24, 2014 to discuss its second quarter 2014 financial results. A live webcast of the conference call will be available online from... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
07/29/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following th... 
Printer Friendly Version
07/24/14AtriCure Reports Second Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $26.5 million – up 29.8% U.S. sales of $19.9 million – up 28.8% International sales of $6.6 million – up 32.9%; 29.1% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 24, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced financial results for the second quarter of 2014. “We are pleased with our performan... 
Printer Friendly Version
07/16/14AtriClip® System Surpasses 34,000 Units Sold
AtriClip is the most widely used device indicated for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 16, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), today announced that it has sold more than 34,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, quickly becoming the top selling device used for eliminating the left... 
Printer Friendly Version
07/03/14AtriCure to Announce Second Quarter 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the second quarter of 2014 on Thursday, July 24, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, July 24, 2014 to discuss its second quarter 2014 financial results. A live webcast of the conference call will be available online from... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
08/13/14 
8:30 a.m. ET
AtriCure, Inc. at Canaccord Genuity Growth Conference
09/04/14
AtriCure, Inc. at Barrington Research 7th Annual Fall Investment Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.